RxDoctor Payments Data

Krithika Ramadas, MD

Allergy · Thousand Oaks, CANPI 1710939715

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,440 of the $6,697 with a category attached, or 66.3%. 17 manufacturers reported payments, led by Optinose US, Inc. at 54.9% of the total. Reporting peaked in 2019 at $3,683 and has fallen 98.9% since, to $42 in 2025.

$6,697in general payments, 2019–2025

Across 80 payments — averaging $83.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$4K
  • Regeneron Healthcare Solutions, Inc.$2K
  • GSK$356
  • AstraZeneca$122
  • Boehringer Ingelheim$67
  • Covis Pharma GmbH$35
  • plus $213 from 11 others

What the payments were for

  • Consulting fees$4,44066%
  • Travel & lodging$93614%
  • Food & beverage$1,21718%
  • Education$1042%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,697 in reported general payments places this provider in the 70th percentile of 117 allergy providers in California.

See all allergy providers in California

Medicare billing

Part B allowed, 2024
$129,955
Medicare patients
224
Services billed
4,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$62,002
Spiriva RespimatTiotropium Bromide50$44,112
XolairOmalizumab11$28,061
Breo ElliptaFluticasone/Vilanterol31$17,945
Incruse ElliptaUmeclidinium Bromide15$10,896
Advair HfaFluticasone Propion/Salmeterol18$9,103
AlvescoCiclesonide12$7,287
Qvar RedihalerBeclomethasone Dipropionate21$7,181
SymbicortBudesonide/Formoterol Fumarate13$7,156
DuleraMometasone/Formoterol13$6,681
BreynaBudesonide/Formoterol Fumarate31$6,581
Fluticasone Propionate HfaFluticasone Propionate14$5,018
Montelukast Sodium311$3,355
Azelastine Hcl54$2,645
Epinephrine16$2,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$356$90,843107 claims
Boehringer IngelheimSpiriva Respimat$67$44,11250 claims
Covis Pharma GmbHAlvesco$35$7,28712 claims
AstraZenecaSymbicort$122$7,15613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 117 allergy providers in California.

Other allergy in Thousand Oaks

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →